within Pharmacolibrary.Drugs.ATC.A;

model A16AB17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 4.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.21,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) used as an enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease, also known as Batten disease). It is approved for intraventricular administration in pediatric patients with CLN2 disease to slow the loss of ambulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric CLN2 patients (mean age 5 years) receiving recommended dosage.</p><h4>References</h4><ol><li><p>Kim, A, et al., &amp; Henshaw, JW (2021). Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. <i>Clinical and translational science</i> 14(2) 635–644. DOI:<a href=&quot;https://doi.org/10.1111/cts.12925&quot;>10.1111/cts.12925</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33202105/&quot;>https://pubmed.ncbi.nlm.nih.gov/33202105</a></p></li><li><p>Hammon, K, et al., &amp; Henshaw, JW (2021). Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease. <i>Clinical and translational science</i> 14(5) 1810–1821. DOI:<a href=&quot;https://doi.org/10.1111/cts.13028&quot;>10.1111/cts.13028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34076336/&quot;>https://pubmed.ncbi.nlm.nih.gov/34076336</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB17;
